

*Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide*

Team name: Oncobiome

Date updated: 2021. 10. 03.

S1: Title & Elevator Pitch/Headline	<ul style="list-style-type: none"> <li>• Successful treatment of breast cancer relies on early diagnosis.</li> <li>• Imaging resolution blind to small nodules and prevents early detection.</li> <li>• Our technology overcomes imaging resolution by assaying stool microbiome.</li> </ul>
S2: The problem and who has it	<ul style="list-style-type: none"> <li>• 370,000 new US breast cancer diagnoses are predicted for 2021.</li> <li>• Breast cancer survival increases 100% for early detection vs. later detection.</li> <li>• Patient discomfort during procedure and image resolution limits lead to later diagnosis.</li> </ul>
S3: The solution	<ul style="list-style-type: none"> <li>• Proprietary biomarkers in the microbiome react to changes in health, as breast cancer.</li> <li>• We propose stool microbiome-based breast cancer screening technology.</li> </ul>
S4: Product (how it addresses the problem)	<ul style="list-style-type: none"> <li>• Specimen collection is home-based with simple shipment to laboratory (non-invasive, low adoption risk).</li> <li>• Screening using proprietary biomarkers assay sample, and results are reported to clinician via ERM and patient.</li> <li>• The results are actionable and the technology benefits all stakeholders.</li> </ul>
S5: Technology	<ul style="list-style-type: none"> <li>• We pioneered a proprietary 5-member marker set with 92% sensitivity and 74% specificity (3 patents).</li> <li>• This method has 100% sensitivity for hard-to-detect lobular cases, compared to 60-80% for imaging.</li> <li>• The markers can identify early-stage cases the best.</li> </ul>
S6: Competing approaches	<ul style="list-style-type: none"> <li>• Mammography, ultrasonography and MRI are plagued by adherence (due to discomfort) and image resolution.</li> <li>• Oncobiome procedure is painless, no radiation involved, overcomes accessibility issues.</li> <li>• Oncobiome excels in early detection of small non-calcifying tumors in hard radiological environments.</li> </ul>
S7: Traction	<ul style="list-style-type: none"> <li>• Concept developed and research began in 2014.</li> <li>• Non-dilutive continuous support since 2014, as grants in proof-of-concept or excellence programs.</li> <li>• We are in constant relationship with clinicians to fine-tune the content of our service.</li> </ul>
S8: Team	<ul style="list-style-type: none"> <li>• Peter Bai, inventor, PhD, scientific leader, involved for 7 years.</li> <li>• Márton Haraszti and András Bulkai for business development, collaborating for 4 years.</li> <li>• The members of my laboratory collaborate on wet chemistry.</li> </ul>
S9: Closing	<ul style="list-style-type: none"> <li>• Late diagnosis of breast cancer leads to preventable mortality and is an unmet medical need.</li> <li>• Stool microbiome can improve early detection and address early breast cancer detection.</li> <li>• The Oncobiome assay benefits patients, the medical staff and the insurance providers.</li> </ul>